If you are switching primarily because of cost, run the math on both manufacturer-direct programs first
Information last revised April 2012
If you notice any new changes in your vision, contact your doctor of optometry right away
Analysis Of The Non-alcoholic Steatohepatitis (NASH) Drug Pipeline & Market: Sizing Up The First Wave By Mavra Nasir, Ph.D., Crystal Hsu, and Peter Bak, Ph.D., Back Bay Life Science Advisors Non-alcoholic steatohepatitis (NASH) 1 is the advanced form of nonalcoholic fatty liver disease (NAFLD), a chronic disease marked by excessive fat accumulation in the liver
If there is worsening glycemic control or failure to achieve targeted glycemic control, significant injection site reactions or allergic reactions, then other antidiabetic therapy should be considered
For example, some patients feel mild nausea or fullness even after years